MyFinsight
Home
Blog
About
Contact
Proceeds from vendor
financing arrangement
$6,786K
Proceeds from exercise of
stock options
$1,311K
Net cash provided by
financing activities
$7,064K
Canceled cashflow
$1,033K
Net increase
(decrease) in cash, cash...
-$140,250K
Canceled cashflow
$7,064K
Stock-based compensation
expense
$13,081K
Depreciation and
amortization expense
$550K
Non-cash lease expense
$116K
Non-cash interest
expense
$79K
Loss on disposal of
property and equipment
-$30K
Other non-current
assets
-$28K
Maturities of marketable
securities
$33,459K
Sales of marketable
securities
$28,648K
Repayments under vendor
financing arrangement
$579K
Payment of issuance
costs from public...
$424K
Payment of debt issuance
costs
$30K
Net cash used in
operating activities
-$144,922K
Canceled cashflow
$13,884K
Net cash used in
investing activities
-$2,392K
Canceled cashflow
$62,107K
Net loss
-$120,854K
Prepaid expenses and
other current assets
$32,847K
Accounts payable and
other liabilities
-$4,804K
Accretion of premium on
marketable securities
-$271K
Gain on sale of
marketable securities
-$30K
Purchases of marketable
securities
$64,278K
Purchases of property and
equipment
$221K
Back
Back
Cash Flow
Dyne Therapeutics, Inc. (DYN)
Dyne Therapeutics, Inc. (DYN)
source: myfinsight.com